AKRO
NASDAQAkero Therapeutics Inc.
Akero Therapeutics Inc. (AKRO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for AKRO in the last 30 days. The most recent was published Jul 14, 2026.
News · 26 weeks10%
2026-05-172026-11-08
Mix090d
No activity.
Activity · 52 weeks339 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRNextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 TherapyAvere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001 Company’s financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis Company to be led by a seasoned team of biotech executives: Andrew Cheng, MD, PhD as CEO, President, & C
- SECSEC Form 15-12G filed by Akero Therapeutics Inc.15-12G - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form 25-NSE filed by Akero Therapeutics Inc.25-NSE - Akero Therapeutics, Inc. (0001744659) (Subject)
- INSIDERDirector Heyman Tomas J. returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Xu Yuan returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERPresident and CEO Cheng Andrew returned 436,837 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Harrison Seth Loring returned 293,762 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Graham G. Walmsley returned 1,302,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Judy Chou returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Scientific Officer Rolph Timothy returned 282,149 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Iwicki Mark T returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Technology Officer Gangloff Scott A. returned 26,351 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Financial Officer White William Richard returned 57,752 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Development Officer Yale Catriona returned 74,800 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERDirector Henderson Jane returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDEROfficer Lamy Patrick returned 29,891 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- INSIDERChief Operating Officer Young Jonathan returned 260,189 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form S-8 POS filed by Akero Therapeutics Inc.S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)
- SECSEC Form POSASR filed by Akero Therapeutics Inc.POSASR - Akero Therapeutics, Inc. (0001744659) (Filer)
AKRO FAQ
8 questionsWhat does Akero Therapeutics Inc. do?
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin...What is the latest news on AKRO?
Quantisnow has not tracked any new filings, ratings or press releases for AKRO in the last 30 days. The most recent wire item was published on July 14, 2026.Where does AKRO stock trade?
Akero Therapeutics Inc. (AKRO) is listed on NASDAQ.What sector and industry is AKRO in?
Akero Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Akero Therapeutics Inc. go public?
Akero Therapeutics Inc. (AKRO) completed its IPO in 2019.What are analysts saying about AKRO?
Across the last 8 analyst actions on Akero Therapeutics Inc., there was 1 upgrade and 0 downgrades. The most recent action was from H.C. Wainwright: Buy with a $72.00 price target on 2025-09-04. Recent price targets range from $30.00 to $83.00.What companies are similar to AKRO?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare AKRO side-by-side with any of them on Quantisnow.How can I track AKRO on Quantisnow?
Quantisnow aggregates Akero Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKRO to receive live email and push alerts on every new disclosure.